Comorbidity and progression of late onset Alzheimer’s disease: A systematic review
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is a neurodegenerative syndrome characterized by multiple dimensions including cognitive decline, decreased daily functioning and psychiatric symptoms. This systematic review aims to investigate the relation between somatic comorbidity burden and progression in late-onset Alzheimer's disease (LOAD). METHODS: We searched four databases for observational studies that examined cross-sectional or longitudinal associations of cognitive or functional or neuropsychiatric outcomes with comorbidity in individuals with LOAD. From the 7966 articles identified originally, 11 studies were included in this review. The Newcastle-Ottawa quality assessment was used. The large variation in progression measures, comorbidity indexes and study designs hampered the ability to perform a meta-analysis. This review was registered with PROSPERO under DIO: 10.15124/CRD42015027046. RESULTS: Nine studies indicated that comorbidity burden was associated with deterioration in at least one of the three dimensions of LOAD examined. Seven out of ten studies investigating cognition found comorbidities to be related to decreased cognitive performance. Five out of the seven studies investigating daily functioning showed an association between comorbidity burden and decreased daily functioning. Neuropsychiatric symptoms (NPS) increased with increasing comorbidity burden in two out of three studies investigating NPS. Associations were predominantly found in studies analyzing the association cross-sectionally, in a time-varying manner or across short follow-up (≤2 years). Rarely baseline comorbidity burden appeared to be associated with outcomes in studies analyzing progression over longer follow-up periods (>2 years). CONCLUSION: This review provides evidence of an association between somatic comorbidities and multifaceted LOAD progression. Given that time-varying comorbidity burden, but much less so baseline comorbidity burden, was associated with the three dimensions prospectively, this relationship cannot be reduced to a simple cause-effect relation and is more likely to be dynamic. Therefore, both future studies and clinical practice may benefit from regarding comorbidity as a modifiable factor with a possibly fluctuating influence on LOAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
An active and socially integrated lifestyle in late life might protect against dementia
Fratiglioni, L., Paillard-Borg, S., & Winblad, B. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00767-7 · Cited by 2,135
Miller, M. D., Paradis, C. F., Houck, P. R., Mazumdar, S., Stack, J. A., Rifai, A. H., Mulsant, B., & Reynolds, C. F. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90005-n · Cited by 1,990 · cited 3×
“Comorbid disease burden was measured using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) [25], Charlson Comorbidity Index (CCI) [26], General Medical Health Rating (GMHR) [15] and some studies counted the comorbidities based on hospital records, physical examination and/ or patient/caregiver report.”
InfluentialThe pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544 · cited 1×
“Comorbidity is defined as any additional co-existing ailment in a patient with a particular index disease [9], in this case LOAD.”
Incidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051
Jyrkkä, J., Enlund, H., Lavikainen, P., Sulkava, R., & Hartikainen, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2116 · Cited by 417
Changing perspectives regarding late-life dementia
Fotuhi, M., Hachinski, V., & Whitehouse, P. J. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.175 · Cited by 291
Carmichael, O. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.284 · Cited by 248
Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
Zhao, Y., Kuo, T.-C., Weir, S., Kramer, M. S., & Ash, A. S. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-108 · Cited by 196
Agüero‐Torres, H., Fratiglioni, L., Guo, Z., Viitanen, M., & Winblad, B. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02464.x · Cited by 147 · cited 3×
“For the extent to which longitudinal studies with measurement intervals longer than 2 years were available [13, 14, 19, 22], the evidence for associations between baseline comorbidity burden and cognitive progression was lacking.”
Cited by
Alzheimer’s Disease: Epidemiology and Clinical Progression
Tahami Monfared, A. A., Byrnes, M. J., White, L. A., & Zhang, Q. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00338-8 · Cited by 629
“A systematic literature review of 11 studies (to 2016) evaluating the influence of comorbid conditions on progression of late-onset AD dementia [56] found associations between comorbidities and declines in cognitive function and functional abilities, as well as increases in neuropsychiatric symptoms [56].”
BackgroundCalderón‐Larrañaga, A., Vetrano, D. L., Ferrucci, L., Mercer, S. W., Marengoni, A., Onder, G., Eriksdotter, M., & Fratiglioni, L. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12843 · Cited by 408
Self-citationAcharya, U. R., Fernandes, S. L., WeiKoh, J. E., Ciaccio, E. J., Fabell, M. K. M., Tanik, U. J., Rajinikanth, V., & Yeong, C. H. (2019) · Journal of Medical Systems · doi:10.1007/s10916-019-1428-9 · Cited by 325
Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg?
Tamagno, E., Guglielmotto, M., Vasciaveo, V., & Tabaton, M. (2021) · Antioxidants · doi:10.3390/antiox10091479 · Cited by 264
McKeever, P. M., Schneider, R., Taghdiri, F., Weichert, A., Multani, N., Brown, R. A., Boxer, A. L., Karydas, A., Miller, B., Robertson, J., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1032-x · Cited by 166
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Metadata
- Authors
- Haaksma, M. L., Vilela, L. R., Marengoni, A., Calderón-Larrañaga, A., Leoutsakos, J.-M. S., Olde Rikkert, M. G. M., & Melis, R. J. F.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-05-04
- Volume
- 12
- Issue
- 5
- Pages
- e0177044
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2610697893
- Cited by
- 94
- References
- 11
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.